Oral Wegovy Outperforms Orforglipron in Weight Loss and Tolerability
The emergence of oral glucagon-like peptide-1 (GLP-1) receptor agonists marks a significant advancement in obesity pharmacotherapy, offering needle-free alternatives to injectable agents. In this context, a new population-adjusted indirect treatment comparison (ITC), to be presented at the Obesity Medicine Association (OMA) 2026 annual meeting, evaluated the relative efficacy and tolerability of oral semaglutide 25 mg (Wegovy® pill) versus orforglipron 36 mg.
Stopping Beta-Blockers after MI: No Benefit Lost in Preserved EF Patients
The role and optimal duration of beta-blocker therapy following myocardial infarction (MI) have been increasingly questioned in the contemporary era of advanced reperfusion strategies and secondary prevention therapies. In a recent study published in the New England Journal of Medicine, investigators evaluated the safety and clinical outcomes associated with discontinuation of long-term beta-blocker therapy in stable post-MI patients without clear ongoing indications such as heart failure or reduced left ventricular ejection fraction (LVEF).
A Practical Framework for Risk Stratification and Management in MASLD
The newly proposed clinical care pathway for metabolic dysfunction-associated steatotic liver disease (MASLD) represents an important step toward standardizing the evaluation and management of one of the most prevalent chronic liver diseases globally. MASLD, closely linked to obesity, type 2 diabetes, and other cardiometabolic risk factors, is frequently managed in primary care and endocrinology settings, necessitating practical, scalable approaches to care.
Prof GIUSEPPE MANCIA
Prof. Enrico Agabiti Rosei at ESH 2019 Milan part 1
Prof. Enrico Agabiti Rosei at ESH 2019 Milan part 2
Professor Dame Anna Dominiczak at ESH 2019 Milan
